BioPorto Enters Intellectual Property License Agreement With Abbott Laboratories

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BioPorto has entered into an agreement with Abbott to cross-license their respective NGAL intellectual property rights (IPR). The parties have signed non-exclusive agreements, which cover all the NGAL related IPR directly and indirectly controlled by both parties – including sub-licenses from Phadia and Cincinnati Children’s Hospital.

Help employers find you! Check out all the jobs and post your resume.

Back to news